NCT06670911View on ClinicalTrials.gov

Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2028

Conditions
Persistent, Recurrent, or Metastatic Cervical Cancer
Interventions
DRUG

Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)

Patients will receive pembrolizumab 100mg IV every 3 weeks plus chemotherapy (paclitaxel 175 mg/m² + carboplatin AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for cisplatin-naïve patients).

Trial Locations (1)

20231050

RECRUITING

Instituto Nacional de Cancer, Rio de Janeiro

All Listed Sponsors
lead

Instituto Nacional de Cancer, Brazil

OTHER_GOV